Kicking KRAS to the kerb
Sunny San Diego
It’s very rare for any oncology category to see lasting success with the first couple of attempts to drug a particular target, especially where the oncogenic addiction is very strong.
It takes a village to figure out how to improve on the original innovators in order to find novel answers to the signals emerging from their work.
Yet often it is the iterations which ultimately move the needle, just as osimertinib and alectinib did in EGFR and ALK non-small cell lung cancer (NSCLC).
Will we see the same trend also happen in KRAS G12C mutated cancers?
In our latest company interview, we’re highlighting the work of Frontier Medicines with their creative next generation strategy to tackling KRAS G12C in people with lung, colon, and pancreatic cancers…
To learn more from our latest oncology expert interview and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
